Yuhan Corporation has signed a memorandum of understanding with Syntekabio Inc. to develop new drugs using genomic big data and an artificial intelligence (AI) platform. Under the agreement, Yuhan and Syntekabio will promote joint research on discovering biological markers or indicators of certain biological condition by analyzing patients genome properties and searching for new drug candidate materials using an AI-based platform. This agreement enables Yuhan and Syntekabio to develop new drugs using genomic big data and an artificial intelligence (AI) platform.